|
Bladder Neoplasm
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge, this is the first report investigating the combined expression profile of TWIST1 and LASS2 in bladder cancer both at mRNA and protein level.
|
30213291 |
2018 |
|
Bladder Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here, we aim to identify a miRNA that targets LASS2 from bladder cancer-associated miRNAs and to reveal its potential functions in bladder cancer cells.
|
30898713 |
2019 |
|
Bladder Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study demonstrated that LASS2 inhibits bladder cancer invasion and chemoresistance through regulation of ERK-Drp1 induced mitochondrial dynamics.
|
29581781 |
2018 |
|
Bladder Neoplasm
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
However, there were no significant correlations between the expression levels of the CERS2 protein with bladder cancer grade/stage or between the IC50 values of cells treated with NDV and <i>CERS2</i> expression.
|
31636736 |
2019 |
|
Bladder Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.
|
26150338 |
2015 |
|
Bladder Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study demonstrates that miR-98 targets LASS2 and regulates bladder cancer chemoresistance through modulation of mitochondrial function.
|
30463687 |
2018 |
|
Bladder Neoplasm
|
0.080 |
Biomarker
|
disease |
BEFREE |
We found that patients with LASS2-negative bladder cancer were linked to poor clinical prognosis.
|
21755371 |
2012 |
|
Bladder Neoplasm
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
We found that a single nucleotide polymorphism (rs8444 C>T) located in the 3'-UTR of LASS2 was significantly associated with the risk of bladder cancer.
|
31577563 |
2019 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Taken together, CERS2 can significantly inhibit breast cancer cell invasion and is associated with the decrease of the V-ATPase activity and extracellular hydrogen ion concentration, and in turn the activation of secreted MMP-2/MMP-9 and degradation of extracellular matrix (ECM), which ultimately suppressed tumor's invasion.
|
25213553 |
2015 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, silencing of TMSG1 increased V-ATPase activity, decreased extracellular pH and in turn the activation of secreted MMP-2, which ultimately promoted metastasis capacity of breast cancer cell.
|
25973015 |
2015 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Recently, we demonstrated that human breast cancer tissue displays increased activity of CerS2, 4, and 6, together with enhanced generation of their products, ceramides C(16:0), C(24:0), and C(24:1).
|
22230369 |
2012 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer.
|
26110566 |
2015 |
|
Breast Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The findings provided the evidence that the LASS2/TMSG1 gene had tumor growth and invasion suppressor function in human breast cancer cell and may provide a promising target for cancer metastasis diagnosis and therapy.
|
25501280 |
2015 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
CerS2 and CerS6 mRNA was significantly elevated in breast cancer tissue compared to paired normal tissue, with approximately half of the individuals showing elevated CerS2 and CerS6 mRNA.
|
19912991 |
2010 |
|
Breast Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that LASS2 expression was significantly lower in drug-resistant Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) human breast cancer cells than the drug-sensitive MCF-7 cells, and low expression of LASS2 was associated with poor prognosis in patients with breast cancer.
|
22580606 |
2013 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
As potential molecular markers for bladder carcinoma, both TWIST1 and LASS2 transcripts seem to play role during the tumorigenesis and development of bladder cancer.
|
30213291 |
2018 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Transcription factor proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 have been reported to be involved in various carcinomas but their expression profiles and prognostic significances in bladder cancer are largely unknown.
|
30213291 |
2018 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The LASS2 gene has been identified as a new tumor metastasis suppressor gene and has been seen to correlate with the degree of invasion and recurrence in carcinomas of prostate, breast, liver, ovarian, and pancreas.
|
21755371 |
2012 |
|
Carcinoma of bladder
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here, we aim to identify a miRNA that targets LASS2 from bladder cancer-associated miRNAs and to reveal its potential functions in bladder cancer cells.
|
30898713 |
2019 |
|
Carcinoma of bladder
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
We found that a single nucleotide polymorphism (rs8444 C>T) located in the 3'-UTR of LASS2 was significantly associated with the risk of bladder cancer.
|
31577563 |
2019 |
|
Carcinoma of bladder
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Thus, LASS2 expression may be correlated with the development and progression of human bladder carcinoma and may be a prognostic indicator for this carcinoma.
|
21755371 |
2012 |
|
Carcinoma of bladder
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study demonstrates that miR-98 targets LASS2 and regulates bladder cancer chemoresistance through modulation of mitochondrial function.
|
30463687 |
2018 |
|
Carcinoma of bladder
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study demonstrated that LASS2 inhibits bladder cancer invasion and chemoresistance through regulation of ERK-Drp1 induced mitochondrial dynamics.
|
29581781 |
2018 |
|
Carcinoma of bladder
|
0.080 |
Biomarker
|
disease |
BEFREE |
miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.
|
26150338 |
2015 |
|
Carcinoma of bladder
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge, this is the first report investigating the combined expression profile of TWIST1 and LASS2 in bladder cancer both at mRNA and protein level.
|
30213291 |
2018 |